Hanmi to distribute Wakamoto’s MaQuid to treat diabetic macular edema

Published: 2013-07-25 06:57:00

Updated: 2013-07-25 06:57:00

Hanmi Pharmaceutical said Tuesday that it has signed a distribution agreement with a Japanese company Wakamoto for the exclusive sale of Wakamoto’ MaQaid for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

An injection designed to directly administer to the patient’s eyeballs by a health care professional, MaQaid is produced...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.